Abstract
Intraurethral application of prostaglandin-E1 (MUSE™) is a well-tolerated pharmacotherapy for erectile dysfunction. However, the physiological mechanisms of drug transfer into the cavernous bodies are not completely clear. Using spongiosography in 35 patients, our study tried to elucidate existing shunt mechanisms. The X-rays show venous drainage through the deep dorsal vein up to the plexus Santorini. The circumflex veins are also contrasted and the cavernous bodies show opacification in their distal portion only. Structures shunting directly between the corpus spongiosum and the cavernous bodies were not demonstrable. Retrograde filling of the cavernous bodies through the deep dorsal vein and its circumflex braches seems to be the most relevant way of drug transfer after intraurethral application of prostaglandin-E1. Diffusion into the cavernous bodies or a systemic mechanism of action does not seem probable.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Porst H . The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 802–815.
Porst H . Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil—a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997; 9: 187–192.
Hauck EW et al. Prostaglandin E1 long-term self-injection programme for treatment of erectile dysfunction—a follow-up of at least 5 years. Andrologia 1999; 31(Suppl 1): S99–S103.
Linet OI, Ogrinc FG . Penile fibrosis during 18 months of intracavemosal therapy with alprostadil (Caverject™). Int J Impot Res 1996; 8: D85.
Porst H et al. Final results of a prospective multicenter-study with self-injection therapy with PGE1 after 4 years of follow-up. Int J Impot Res 1996; 8: D118.
Padma-Nathan H et al. Hemodynamic effects of intraurethral alprostadil: the medicated urethral system for erection (MUSE™). J Urol 1994; 151: 345, A469.
Shokeir AA, Alserafi MA, Mutabagani H . Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU Int 1999; 83: 812–815.
Porst H . Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil—a comparative study in 103 patients with erectile dysfunction. Reply. Int J Impot Res 1998; 10: 62.
Engel JD, McVary KT . Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy. Urology 1998; 51: 687–692.
Lewis RW . Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil—a comparative study in 103 patients with erectile dysfunction. Letter to the Editor. Int J Impot Res 1998; 10: 61.
Engelhardt PF, Plas E, Hübner WA, Pflüger H . Comparison of intraurethral liposomal and intracavernosal prostaglandin-E1 in the management of erectile dysfunction. Br J Urol 1998; 81: 441–444.
Hatzichristou DG . Current treatment and future perspectives for erectile dysfunction. Int J Impot Res 1998; 10(Suppl 1): S3–S13.
Meinhardt W, Kropman RF, Vermeij P . Comparative tolerability and efficacy of treatments for impotence. Drug Saf 1999; 20: 133–146.
Williams G et al. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. Br J Urol 1998; 82: 847–854.
Costabile RA et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998; 160: 1325–1328.
O'Leary MP et al. Transurethral alprostadil improves quality of life for patients and partners. Int J Impot Res 1996; 8: A68.
Wilke RJ et al. Quality of life effects of Alprostadil therapy for erectile dysfunction in the US and Europe. Int J Impot Res 1996; 8: 113, A58.
Vardi Y, Saenz de Tejada I . Transfer of vasodilator drugs from the glans and corpus spongiosum to the corpora cavernosa. Int J Impot Res 1996; 8: 130, D33.
Vardi Y, Saenz de Tejada I . Functional and radiologic evidence of vascular communication between the spongiosal and cavernosal compartments of the penis. Urology 1997; 49: 749–752.
Tam PY et al. Hemodynamic effects of transurethral alprostadil measured by color duplex ultrasonography in men with erectile dysfunction. J Urol 1998; 160: 1321–1324.
Wagner G, Bro-Rasmussen F, Willis EA, Nielsen MH . New theory on the mechanism of erection involving hitherto undescribed vessels. Lancet 1982; 2: 416–418.
Gesundheit N et al. The pharmacokinetics of transurethral alprostadil (Prostaglandin E1) in men with erectile dysfunction. J Urol 1997; 157(Suppl): 259, A1013.
Chiang HS, Kao YH, Sheu MT . Papaverine and prostaglandin E1 gel applications for impotence. Ann Acad Med Singapore 1995; 24: 767–769.
Padma-Nathan H et al. Improved erectile response to transurethral alprostadil by use of a novel, adjustable penile band. J Urol 1997; 157(Suppl): 181, A704.
Lue TF, Tanagho EA . Functional anatomy and mechanism of penile erection. In: Tanagho EA, Lue TF, McClure RD (eds). Contemporary Management of Impotence and Infertility. Williams & Williams: Baltimore, 1988, pp 39–50.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bschleipfer, T., Cimniak, HU., Beckert, R. et al. Possible hemodynamic pathways of intraurethral prostaglandin-E1 (MUSE™). Int J Impot Res 16, 365–368 (2004). https://doi.org/10.1038/sj.ijir.3901163
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901163